High Prevalence of Risk Factors in Coronary Artery Disease in EUROPA Gives HOPE for ACE Inhibitors after PEACE
Background: Routine use of ACE inhibitors (ACE-I) as secondary preventive therapy for all patients with coronary artery disease (CAD) is challenged by the PEACE trial. Currently it is unclear to what extent ACE-I should be used in CAD populations. Purpose: To analyze the prevalence of left ventricul...
Gespeichert in:
| Veröffentlicht in: | Cardiology 2008-01, Vol.111 (1), p.63-67 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 67 |
|---|---|
| container_issue | 1 |
| container_start_page | 63 |
| container_title | Cardiology |
| container_volume | 111 |
| creator | Pedersen, Sune A. Galatius, Søren Hecht Olsen, Michael Kühn Madsen, Bente Kyst Madsen, Jan Nielsen, Olav W. |
| description | Background: Routine use of ACE inhibitors (ACE-I) as secondary preventive therapy for all patients with coronary artery disease (CAD) is challenged by the PEACE trial. Currently it is unclear to what extent ACE-I should be used in CAD populations. Purpose: To analyze the prevalence of left ventricular systolic dysfunction, diabetes, myocardial infarction and hypertension in an unselected and consecutive population of patients with documented CAD and evaluate the potential need for ACE-I treatment in a real-life scenario. Methods: We searched a database containing all invasive cardiac investigations in three hospitals in Copenhagen from July 1, 2000 to June 30, 2003. Patients with no angiographic sign of CAD were excluded. Results: Among 7,345 patients, 4,180 had stable CAD and 3,165 had acute coronary syndrome (ACS). Among the stable CAD patients 78% had at least one of the following indications for treatment with an ACE-I: left ventricular ejection fraction 159 mm Hg (21%), and/or myocardial infarction (42%). Among ACS patients, 90% had an indication for ACE-I treatment. Conclusion: Depending on the definitions, at least 78% of the patients with stable CAD and 90% with ACS have an accepted indication for treatment with an ACE-I. |
| doi_str_mv | 10.1159/000113430 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_274732688</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69358568</sourcerecordid><originalsourceid>FETCH-LOGICAL-c331t-9edf20dde6981132d7fa928df9e74f18617b54764099c072969fbf23f13dcdc93</originalsourceid><addsrcrecordid>eNpdkctLAzEQxoMotlYP3kWCB8HDah67m82x1O0DCi3Fnpd0d9Kmj40mbcH_3tQWC54-ZuY3H_NA6J6SV0oT-UYIoZTHnFygJo0ZjaRI6CVqhnwWpZyyBrrxfhnCWMTsGjVoxrjkMmmium_mCzx2sFdrqEvAVuOJ8SvcVeXWOo9NjTvW2Vq5b9x2WwjybjwoD4dSPp2Mxm3cM3vwuD8a51hbh9udHA_qhZmZXwulQxse5yF9i660Wnu4O2kLTbv5R6cfDUe9Qac9jErO6TaSUGlGqgpSmYXNWCW0kiyrtAQRa5qlVMySWKQxkbIkgslU6plmXFNelVUpeQs9H30_nf3agd8WG-NLWK9VDXbni1TyJEvSLIBP_8Cl3bk6zFYwEQvO0uwAvRyh0lnvHeji05lNuEhBSXH4QPH3gcA-ngx3sw1UZ_J08gA8HIGVcnNwZ-DY_wMfwIYr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>274732688</pqid></control><display><type>article</type><title>High Prevalence of Risk Factors in Coronary Artery Disease in EUROPA Gives HOPE for ACE Inhibitors after PEACE</title><source>MEDLINE</source><source>Karger Journals</source><source>Alma/SFX Local Collection</source><creator>Pedersen, Sune A. ; Galatius, Søren ; Hecht Olsen, Michael ; Kühn Madsen, Bente ; Kyst Madsen, Jan ; Nielsen, Olav W.</creator><creatorcontrib>Pedersen, Sune A. ; Galatius, Søren ; Hecht Olsen, Michael ; Kühn Madsen, Bente ; Kyst Madsen, Jan ; Nielsen, Olav W.</creatorcontrib><description>Background: Routine use of ACE inhibitors (ACE-I) as secondary preventive therapy for all patients with coronary artery disease (CAD) is challenged by the PEACE trial. Currently it is unclear to what extent ACE-I should be used in CAD populations. Purpose: To analyze the prevalence of left ventricular systolic dysfunction, diabetes, myocardial infarction and hypertension in an unselected and consecutive population of patients with documented CAD and evaluate the potential need for ACE-I treatment in a real-life scenario. Methods: We searched a database containing all invasive cardiac investigations in three hospitals in Copenhagen from July 1, 2000 to June 30, 2003. Patients with no angiographic sign of CAD were excluded. Results: Among 7,345 patients, 4,180 had stable CAD and 3,165 had acute coronary syndrome (ACS). Among the stable CAD patients 78% had at least one of the following indications for treatment with an ACE-I: left ventricular ejection fraction <0.45 (20%), hypertension (39%), diabetes (19%), systolic blood pressure >159 mm Hg (21%), and/or myocardial infarction (42%). Among ACS patients, 90% had an indication for ACE-I treatment. Conclusion: Depending on the definitions, at least 78% of the patients with stable CAD and 90% with ACS have an accepted indication for treatment with an ACE-I.</description><identifier>ISSN: 0008-6312</identifier><identifier>EISSN: 1421-9751</identifier><identifier>DOI: 10.1159/000113430</identifier><identifier>PMID: 18239395</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Angiotensin-Converting Enzyme Inhibitors - therapeutic use ; Cardiology ; Cardiovascular disease ; Clinical outcomes ; Comorbidity ; Coronary Artery Disease - epidemiology ; Coronary vessels ; Denmark - epidemiology ; Diabetes Mellitus - epidemiology ; Drug therapy ; Female ; Heart Diseases - epidemiology ; Heart Diseases - prevention & control ; Humans ; Hypertension - epidemiology ; Inhibitor drugs ; Male ; Middle Aged ; Original Research</subject><ispartof>Cardiology, 2008-01, Vol.111 (1), p.63-67</ispartof><rights>2008 S. Karger AG, Basel</rights><rights>(c) 2008 S. Karger AG, Basel.</rights><rights>Copyright (c) 2008 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c331t-9edf20dde6981132d7fa928df9e74f18617b54764099c072969fbf23f13dcdc93</citedby><cites>FETCH-LOGICAL-c331t-9edf20dde6981132d7fa928df9e74f18617b54764099c072969fbf23f13dcdc93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18239395$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pedersen, Sune A.</creatorcontrib><creatorcontrib>Galatius, Søren</creatorcontrib><creatorcontrib>Hecht Olsen, Michael</creatorcontrib><creatorcontrib>Kühn Madsen, Bente</creatorcontrib><creatorcontrib>Kyst Madsen, Jan</creatorcontrib><creatorcontrib>Nielsen, Olav W.</creatorcontrib><title>High Prevalence of Risk Factors in Coronary Artery Disease in EUROPA Gives HOPE for ACE Inhibitors after PEACE</title><title>Cardiology</title><addtitle>Cardiology</addtitle><description>Background: Routine use of ACE inhibitors (ACE-I) as secondary preventive therapy for all patients with coronary artery disease (CAD) is challenged by the PEACE trial. Currently it is unclear to what extent ACE-I should be used in CAD populations. Purpose: To analyze the prevalence of left ventricular systolic dysfunction, diabetes, myocardial infarction and hypertension in an unselected and consecutive population of patients with documented CAD and evaluate the potential need for ACE-I treatment in a real-life scenario. Methods: We searched a database containing all invasive cardiac investigations in three hospitals in Copenhagen from July 1, 2000 to June 30, 2003. Patients with no angiographic sign of CAD were excluded. Results: Among 7,345 patients, 4,180 had stable CAD and 3,165 had acute coronary syndrome (ACS). Among the stable CAD patients 78% had at least one of the following indications for treatment with an ACE-I: left ventricular ejection fraction <0.45 (20%), hypertension (39%), diabetes (19%), systolic blood pressure >159 mm Hg (21%), and/or myocardial infarction (42%). Among ACS patients, 90% had an indication for ACE-I treatment. Conclusion: Depending on the definitions, at least 78% of the patients with stable CAD and 90% with ACS have an accepted indication for treatment with an ACE-I.</description><subject>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</subject><subject>Cardiology</subject><subject>Cardiovascular disease</subject><subject>Clinical outcomes</subject><subject>Comorbidity</subject><subject>Coronary Artery Disease - epidemiology</subject><subject>Coronary vessels</subject><subject>Denmark - epidemiology</subject><subject>Diabetes Mellitus - epidemiology</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Heart Diseases - epidemiology</subject><subject>Heart Diseases - prevention & control</subject><subject>Humans</subject><subject>Hypertension - epidemiology</subject><subject>Inhibitor drugs</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Original Research</subject><issn>0008-6312</issn><issn>1421-9751</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkctLAzEQxoMotlYP3kWCB8HDah67m82x1O0DCi3Fnpd0d9Kmj40mbcH_3tQWC54-ZuY3H_NA6J6SV0oT-UYIoZTHnFygJo0ZjaRI6CVqhnwWpZyyBrrxfhnCWMTsGjVoxrjkMmmium_mCzx2sFdrqEvAVuOJ8SvcVeXWOo9NjTvW2Vq5b9x2WwjybjwoD4dSPp2Mxm3cM3vwuD8a51hbh9udHA_qhZmZXwulQxse5yF9i660Wnu4O2kLTbv5R6cfDUe9Qac9jErO6TaSUGlGqgpSmYXNWCW0kiyrtAQRa5qlVMySWKQxkbIkgslU6plmXFNelVUpeQs9H30_nf3agd8WG-NLWK9VDXbni1TyJEvSLIBP_8Cl3bk6zFYwEQvO0uwAvRyh0lnvHeji05lNuEhBSXH4QPH3gcA-ngx3sw1UZ_J08gA8HIGVcnNwZ-DY_wMfwIYr</recordid><startdate>20080101</startdate><enddate>20080101</enddate><creator>Pedersen, Sune A.</creator><creator>Galatius, Søren</creator><creator>Hecht Olsen, Michael</creator><creator>Kühn Madsen, Bente</creator><creator>Kyst Madsen, Jan</creator><creator>Nielsen, Olav W.</creator><general>S. Karger AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20080101</creationdate><title>High Prevalence of Risk Factors in Coronary Artery Disease in EUROPA Gives HOPE for ACE Inhibitors after PEACE</title><author>Pedersen, Sune A. ; Galatius, Søren ; Hecht Olsen, Michael ; Kühn Madsen, Bente ; Kyst Madsen, Jan ; Nielsen, Olav W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c331t-9edf20dde6981132d7fa928df9e74f18617b54764099c072969fbf23f13dcdc93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Angiotensin-Converting Enzyme Inhibitors - therapeutic use</topic><topic>Cardiology</topic><topic>Cardiovascular disease</topic><topic>Clinical outcomes</topic><topic>Comorbidity</topic><topic>Coronary Artery Disease - epidemiology</topic><topic>Coronary vessels</topic><topic>Denmark - epidemiology</topic><topic>Diabetes Mellitus - epidemiology</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Heart Diseases - epidemiology</topic><topic>Heart Diseases - prevention & control</topic><topic>Humans</topic><topic>Hypertension - epidemiology</topic><topic>Inhibitor drugs</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Original Research</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pedersen, Sune A.</creatorcontrib><creatorcontrib>Galatius, Søren</creatorcontrib><creatorcontrib>Hecht Olsen, Michael</creatorcontrib><creatorcontrib>Kühn Madsen, Bente</creatorcontrib><creatorcontrib>Kyst Madsen, Jan</creatorcontrib><creatorcontrib>Nielsen, Olav W.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pedersen, Sune A.</au><au>Galatius, Søren</au><au>Hecht Olsen, Michael</au><au>Kühn Madsen, Bente</au><au>Kyst Madsen, Jan</au><au>Nielsen, Olav W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High Prevalence of Risk Factors in Coronary Artery Disease in EUROPA Gives HOPE for ACE Inhibitors after PEACE</atitle><jtitle>Cardiology</jtitle><addtitle>Cardiology</addtitle><date>2008-01-01</date><risdate>2008</risdate><volume>111</volume><issue>1</issue><spage>63</spage><epage>67</epage><pages>63-67</pages><issn>0008-6312</issn><eissn>1421-9751</eissn><abstract>Background: Routine use of ACE inhibitors (ACE-I) as secondary preventive therapy for all patients with coronary artery disease (CAD) is challenged by the PEACE trial. Currently it is unclear to what extent ACE-I should be used in CAD populations. Purpose: To analyze the prevalence of left ventricular systolic dysfunction, diabetes, myocardial infarction and hypertension in an unselected and consecutive population of patients with documented CAD and evaluate the potential need for ACE-I treatment in a real-life scenario. Methods: We searched a database containing all invasive cardiac investigations in three hospitals in Copenhagen from July 1, 2000 to June 30, 2003. Patients with no angiographic sign of CAD were excluded. Results: Among 7,345 patients, 4,180 had stable CAD and 3,165 had acute coronary syndrome (ACS). Among the stable CAD patients 78% had at least one of the following indications for treatment with an ACE-I: left ventricular ejection fraction <0.45 (20%), hypertension (39%), diabetes (19%), systolic blood pressure >159 mm Hg (21%), and/or myocardial infarction (42%). Among ACS patients, 90% had an indication for ACE-I treatment. Conclusion: Depending on the definitions, at least 78% of the patients with stable CAD and 90% with ACS have an accepted indication for treatment with an ACE-I.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>18239395</pmid><doi>10.1159/000113430</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-6312 |
| ispartof | Cardiology, 2008-01, Vol.111 (1), p.63-67 |
| issn | 0008-6312 1421-9751 |
| language | eng |
| recordid | cdi_proquest_journals_274732688 |
| source | MEDLINE; Karger Journals; Alma/SFX Local Collection |
| subjects | Angiotensin-Converting Enzyme Inhibitors - therapeutic use Cardiology Cardiovascular disease Clinical outcomes Comorbidity Coronary Artery Disease - epidemiology Coronary vessels Denmark - epidemiology Diabetes Mellitus - epidemiology Drug therapy Female Heart Diseases - epidemiology Heart Diseases - prevention & control Humans Hypertension - epidemiology Inhibitor drugs Male Middle Aged Original Research |
| title | High Prevalence of Risk Factors in Coronary Artery Disease in EUROPA Gives HOPE for ACE Inhibitors after PEACE |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T02%3A53%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20Prevalence%20of%20Risk%20Factors%20in%20Coronary%20Artery%20Disease%20in%20EUROPA%20Gives%20HOPE%20for%20ACE%20Inhibitors%20after%20PEACE&rft.jtitle=Cardiology&rft.au=Pedersen,%20Sune%20A.&rft.date=2008-01-01&rft.volume=111&rft.issue=1&rft.spage=63&rft.epage=67&rft.pages=63-67&rft.issn=0008-6312&rft.eissn=1421-9751&rft_id=info:doi/10.1159/000113430&rft_dat=%3Cproquest_cross%3E69358568%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=274732688&rft_id=info:pmid/18239395&rfr_iscdi=true |